During its January 2008 meeting, the Agencyâs Committee for Medicinal Products for Human Use (CHMP) adopted a scientific opinion recommending the inclusion of a new warning stating that the use of rosiglitazone in patients with ischemic heart disease and/or peripheral arterial disease is not recommended.
The CHMP also adopted an opinion recommending the addition of a new contraindication stating that rosiglitazone must not be used in patients with an acute coronary syndrome, such as angina or some types of myocardial infarction, because the medicine has not been studied in controlled trials in this specific patient group.
The recommended changes to the product information have been made as a follow-up measure to the re-assessment of the benefits and risks of rosiglitazone and pioglitazone, another antidiabetic medicine. This re-assessment was finalised by the CHMP in October 2007, concluding that the benefits of both medicines continued to outweigh their risks in their approved indications, but that the product information for rosiglitazone should be changed.
Looking more globally at antidiabetic medicines and the cardiovascular risk associated with their use, the CHMP and its Efficacy Working Party are currently re-examining their existing âNote for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitusâ to decide whether changes are needed. A concept paper, setting out the main points for revision, is expected to be released in February.
For further information, please visit: